240 related articles for article (PubMed ID: 12949426)
1. Adjuvant hormonal treatment for prostate cancer: the bicalutamide early prostate cancer program.
Wirth MP; Froehner M
Oncology; 2003; 65 Suppl 1():1-4. PubMed ID: 12949426
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant hormonal treatment - the bicalutamide early prostate cancer program.
Wirth MP; Hakenberg OW; Froehner M
Front Radiat Ther Oncol; 2008; 41():39-48. PubMed ID: 18544984
[TBL] [Abstract][Full Text] [Related]
3. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.
McLeod DG; Iversen P; See WA; Morris T; Armstrong J; Wirth MP;
BJU Int; 2006 Feb; 97(2):247-54. PubMed ID: 16430622
[TBL] [Abstract][Full Text] [Related]
4. The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer.
See WA; Tyrrell CJ;
J Cancer Res Clin Oncol; 2006 Aug; 132 Suppl 1():S7-16. PubMed ID: 16896884
[TBL] [Abstract][Full Text] [Related]
5. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.
See WA; Wirth MP; McLeod DG; Iversen P; Klimberg I; Gleason D; Chodak G; Montie J; Tyrrell C; Wallace DM; Delaere KP; Vaage S; Tammela TL; Lukkarinen O; Persson BE; Carroll K; Kolvenbag GJ;
J Urol; 2002 Aug; 168(2):429-35. PubMed ID: 12131282
[TBL] [Abstract][Full Text] [Related]
6. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme.
Tyrrell CJ; Payne H; See WA; McLeod DG; Wirth MP; Iversen P; Armstrong J; Morris C;
Radiother Oncol; 2005 Jul; 76(1):4-10. PubMed ID: 16145740
[TBL] [Abstract][Full Text] [Related]
7. Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer.
See W; Iversen P; Wirth M; McLeod D; Garside L; Morris T
Eur Urol; 2003 Nov; 44(5):512-7; discussion 517-8. PubMed ID: 14572747
[TBL] [Abstract][Full Text] [Related]
8. Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program.
Iversen P; Wirth MP; See WA; McLeod DG; Klimberg I; Gleason D; Chodak G; Montie J; Tyrrell C; Wallace DM; Delaere KP; Lundmo P; Tammela TL; Johansson JE; Morris T; Carroll K;
Urology; 2004 May; 63(5):928-33. PubMed ID: 15134983
[TBL] [Abstract][Full Text] [Related]
9. Bicalutamide: in early-stage prostate cancer.
Carswell CI; Figgitt DP
Drugs; 2002; 62(17):2471-79; discussion 2480-1. PubMed ID: 12421104
[TBL] [Abstract][Full Text] [Related]
10. Bicalutamide monotherapy for early stage prostate cancer: an update.
Iversen P
J Urol; 2003 Dec; 170(6 Pt 2):S48-52; discussion S52-4. PubMed ID: 14610410
[TBL] [Abstract][Full Text] [Related]
11. Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer.
Gravina GL; Festuccia C; Galatioto GP; Muzi P; Angelucci A; Ronchi P; Costa AM; Bologna M; Vicentini C
Urology; 2007 Oct; 70(4):728-33. PubMed ID: 17991545
[TBL] [Abstract][Full Text] [Related]
12. The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer.
Iversen P; Roder MA
Expert Rev Anticancer Ther; 2008 Mar; 8(3):361-9. PubMed ID: 18366284
[TBL] [Abstract][Full Text] [Related]
13. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy.
Di Lorenzo G; Perdonà S; De Placido S; D'Armiento M; Gallo A; Damiano R; Pingitore D; Gallo L; De Sio M; Autorino R
J Urol; 2005 Dec; 174(6):2197-203. PubMed ID: 16280763
[TBL] [Abstract][Full Text] [Related]
14. Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer.
Wellington K; Keam SJ
Drugs; 2006; 66(6):837-50. PubMed ID: 16706554
[TBL] [Abstract][Full Text] [Related]
15. Emerging role of adjuvant hormonal therapy.
Mcleod DG
Urology; 2002 Sep; 60(3 Suppl 1):13-20; discussion 21. PubMed ID: 12231039
[TBL] [Abstract][Full Text] [Related]
16. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression.
Wirth M; Tyrrell C; Wallace M; Delaere KP; Sánchez-Chapado M; Ramon J; Hetherington J; Pina F; Heynes CF; Borchers TM; Morris T; Stone A
Urology; 2001 Aug; 58(2):146-51. PubMed ID: 11489683
[TBL] [Abstract][Full Text] [Related]
17. Bicalutamide treatment for locally advanced prostate cancer.
Anderson J
Hosp Med; 2000 Sep; 61(9):660-3. PubMed ID: 11048610
[TBL] [Abstract][Full Text] [Related]
18. Apples and oranges. Re: 7.4-year update of the ongoing bicalutamide Early Prostate Cancer (EPC) trial programme.
Sternberg CN
BJU Int; 2006 Mar; 97(3):435-8. PubMed ID: 16469001
[No Abstract] [Full Text] [Related]
19. New indication sought for bicalutamide.
Oncology (Williston Park); 2000 May; 14(5):654, 772. PubMed ID: 10853458
[No Abstract] [Full Text] [Related]
20. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the Early Prostate Cancer Program.
Brawer MK
BJU Int; 2003 Apr; 91(6):465-6. PubMed ID: 12656893
[No Abstract] [Full Text] [Related]
[Next] [New Search]